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Abstract 
Background 
Macroscopic cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion 
(HITHOC) is a new multimodal approach for selected patients with primary and secondary 
pleural tumors, which may provide the patient with better local tumor control and increased 
overall survival rate. 
Methods 
We present a single-center study including 20 patients undergoing cytoreductive surgery and 
HITHOC between September 2008 and April 2013 at the University Medical Center 
Regensburg, Germany. Objective of the study was to describe the perioperative, anaesthetic 
management with special respect to pain and complication management. 
Results 
Anaesthesia during this procedure is characterized by increased intrathoracic airway and 
central venous pressure, hemodynamic alterations and the risk of systemic hypo- and 
hyperthermia. Securing an adequate intravascular volume is one of the primary goals to 
prevent decreased cardiac output as well as pulmonary edema. Transfusion of packed red 
blood cells (PRBC) was necessary in seven of 20 (35%) patients. Only two patients (10%) 
showed an impairment of coagulation in postoperative laboratory analysis. Perioperative 
forced diuresis is recommended to prevent postoperative renal insufficiency. Supplementary 
thoracic epidural analgesia in 13 patients (65%) showed a significant reduction of post-
operative pain compared with peroral administration of opioid and non-opioid analgesics. 
Conclusion 
This article summarizes important experiences of the anaesthesiological and intensive care 
management in patients undergoing HITHOC. 
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Background 
In spite of intensive research efforts, there has not yet been any success in establishing a 
standard treatment regime with curative intention for patients with primary (malignant pleural 
mesothelioma) and secondary (thymoma Masaoka stage IVa) malignant pleural tumors. 
Recently a new multimodal treatment approach, including radio-, chemotherapy and 
macroscopic complete cytoreductive surgery (pleurectomy/decortication or extrapleural 
pneumonectomy) combined with HITHOC is available, which must be analysed as a 
potential curative treatment strategy in the upcoming years [1-3]. According to the success of 
cytoreductive surgery and intraperitoneal hyperthermic perfusion chemotherapy (HIPEC) for 
peritoneal malignancies [4], results of first studies are promising reaching a decreased 
recurrence rate and an improved long-term survival [5,6]. Although in the meantime the 
intra- and postoperative morbidity and mortality depending on patient’s disorders, 
intraoperative cytostatic concentrations [7] and the degree of surgical resection [8] could be 
reduced, cytoreductive surgery and HITHOC is a real challenge for the anaesthesiologist with 
respect to intraoperative management and postoperative pain therapy. Due to this issue being 
seldom observed and reported in literature so far [9] anaesthetic management is described and 
discussed in the following report in detail. 
Methods 
This study is a retrospective review of 20 patients with primary and secondary malignant 
pleural tumors who underwent pleurectomy/decortication (P/D: n = 18) or extrapleural 
pneumonectomy (EPP: n = 2) followed by HITHOC with cisplatin at the Department of 
Thoracic Surgery of the University Medical Center Regensburg between September 2008 and 
April 2013. The ethics committee of the University of Regensburg approved the study 
protocol. An article describing the surgical procedure of this clinical trial has already been 
published [6]. To protect confidentiality, all data have been anonymised. 
Premedication 
The day before surgery, all patients were visited for a detailed history and physical 
examination by the anaesthesiologist. Particular emphasis was placed on cardiopulmonary 
risk evaluation according to the recommendations of national and international scientific 
societies [10,11]. To evaluate the operability, functional lung testing (clinical evaluation, 
spirometry, blood gas analysis) was performed on all patients. For preoperative anxiolysis 
patients were treated orally with dikaliumclorazepat 10 – 20 mg (Tranxilium®, Sanofi-
Aventis GmbH, Frankfurt am Main, Germany) in the evening and midazolam 3.75 - 7.5 mg 
(Dormicum®, Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany) in the morning before 
surgery. 
Induction 
On admission to the operating theater, all patients were monitored by electrocardio-gram, 
pulse oximetry, and invasive arterial blood pressure (radial artery). Before induction of 
general anaesthesia 13 of 20 patients (65%) additionally received a thoracic epidural catheter 
in sitting position (mean Th 7/8, range Th 6/7-8/9). After a test dose of 3 ml of ropivacaine 
0.75% (Naropin®, AstraZeneca GmbH, Wien, Austria), further 7 ml of ropivacaine 0.75% 
and sufentanil 10 µg (Sufentanil Curamed®, DeltaSelect GmbH, Dreieich, Germany) was 
administered in the epidural space. After preoxygenation, general anaesthesia was induced 
with propofol 2–3 mg•kg−1 (Propofol-®Lipuro, B. Braun Medical AG, Sempach, 
Switzerland), fentanyl 2–4 µg•kg−1 (Fentanyl®-Janssen, Janssen Pharmaceutica N. V., 
Beerse, Belgium) and rocuronium 0.6 mg•kg1 (Esmeron®, MSD Merck Sharp & Dohme AG, 
Luzern, Switzerland), and maintained with inhaled sevoflurane (Sevoflurane®, Baxter 
Deutschland GmbH, Unterschleißheim, Germany). Intraoperative analgesia was provided 
with repeated epidural administration of local anaesthetics (ropivacaine 0.75%), or 
intravenous doses of fentanyl in patients without epidural catheter. For mechanical ventilation 
with lung isolation, the trachea was intubated with a 39- (respectively 37-) French (Fr) left-
sided double-lumen tube, and correct placement was confirmed with fiberoptic 
bronchoscopy. Additionally central venous pressure (internal jugular vein), oesophageal and 
buccal body’s core temperature, CO2 concentration, airway pressure and urinary output were 
monitored. Finally, patients were placed in a lateral position on a heating/cooling blanket 
(Bair Hugger®, Arizant Medical, Inc., Eden Prairie, MN, USA) for maintaining normal body 
temperature and stabilized with pneumatic boots. All patients received prophylactic 
antibiotics preoperatively (cefuroxime 1.5 g). Immediately before starting the operation the 
bronchial or tracheal lumen of the double–lumen tube was clamped and disconnected, and 
oxygenation with one lung ventilation (OLV) started. The most important goal during OLV is 
to ensure adequate oxygenation and to prevent hypoxemia as well as acute lung injury (ALI). 
Therefore, we used protective lung ventilation (PLV) with low tidal volumes (5 ml kg−1), 
limiting plateau pressure and positive end-exspiratory pressure (PEEP) of approximately 5–
10 cm H2O. Oxygen administration with or without continuous positive airway pressure 
(CPAP) to the non-ventilated lung was an effective treatment to improve the arterial 
oxygenation. 
Surgery 
In the current study patients underwent a anterolateral thoracotomy through the fifth 
intercostal space with the aim of an extensive cytoreductive surgery performed with lung-
sparing radical P/D or more invasive EPP, when necessary to achieve macroscopic complete 
tumour resection. Patients with thymoma primarily had radical thymectomy via median 
sternotomy. In 14 patients (70%) a second access thoracotomy was necessary to complete the 
surgical cytoreduction in the phrenicocostal recess, or for partial resection of the diaphragm. 
Extrapleural dissection between the parietal pleura and the chest wall, diaphragm, and 
mediastinum was continued until the hilar structures were free. After separating the visceral 
pleura from the lung, wedge resections of infiltrated parts of the lung were performed, if 
required. Extended resections (partial or complete) of the pericardium, diaphragm, or chest 
wall were reconstructed with bovine or polytetrafluor-ethylene patches. After completion of 
the surgical cytoreduction larger air leakages were sutured, chest tubes (24 Fr) were inserted 
and the unventilated lung expanded. 
Chemotherapy 
After wound closure of the thorax a ThermoChemTM HAT-1000 System (Therma-
Solutions®, White Bear Lake, MN, USA) was set up to establish a continuous thoracic 
perfusion. There were two or three inflow catheters placed apically in the anterior and 
posterior pleural cavity and one or two outflow catheters placed caudally in the anterior and 
posterior diaphragm sinus. Temperature was measured continuously by two sensors in the 
inflow and outflow catheters. The priming volume (2–4 L sodium chloride solution or 
Ringer’s lactate solution) was pumped into the pleural cavity until stabilization of the 
circulation and homogenous intrathoracic temperature of 42°C were reached. Afterward, 
cisplatin (100 to 150 mg•m−2 body surface area) was administered and perfusion was 
continued for one hour with approximately 1.2 – 1.5 L•min−1 pump flow. In the meantime the 
application of peep (5–10 mmHg) may increase the lung surface for cisplatin and reduce or 
prevent pulmonary atelectasis. At the end of the procedure, the perfusion fluid was removed 
and the tubes were disconnected and left in the pleural cavity as standard thoracic drains with 
mild suction (20 cm H2O) [6]. 
Postoperative management 
Extubation of the lung directly after surgery in the operation theater was preferred in all 
cases. Postoperatively all patients were transferred to the cardiothoracic intensive care unit 
(ICU) and received standard monitoring. For postoperative pain therapy, a continuous 
epidural infusion with ropivacaine 0.2% and sufentanil 1 µg•ml−1 was administered at 7 
ml•h−1 in patients with epidural catheter. Additional bolus doses of 5 ml ropivacaine 0.2% up 
to every 45 min for on-demand self-administration were set in the patient-controlled epidural 
analgesia (PCEA) infusion pump. As a basic pain treatment, all patients received 
oxycodone/naloxone 10/5 mg (Targin®, Mundipharma GmbH, Limburg (Lahn), Germany) 
orally every 12 hours and metamizol 1 g (Novamin-sulfon-ratiopharm®, Ratiopharm GmbH, 
Ulm, Germany) every 6 hours, and for acute treatment morphine 10 mg respectively 
hydromorphone 1.3 mg (drugstore, University Medical Center Regensburg, Germany) as 
needed. As a supplement, the administration of ibuprofen 400 mg (Ibuhexal®, Hexal AG, 
Holzkirchen, Germany), orally, every 8 hours was possible. To optimize pain therapy all 
patients were visited by an anaesthesiologist from the acute pain service twice a day over a 
five day period. The sufficiency of the postoperative analgesia was evaluated by the 
numerical rating scale (NRS), with zero representing no pain and 10 being the worst pain 
possible. The aim was to achieve a pain intensity of three or less on the NRS. 
Patients undergoing cytoreductive surgery and HITHOC are at very high risk of venous 
thromboembolism. Preoperatively we started thromboembolism prophylaxis with low-
molecular-weight heparin (3000 IU of Mono Embolex®, Novartis Pharma GmbH, Nürnberg, 
Germany). Six hours after surgery treatment with continuous intravenous unfractionated 
heparin and a target aPTT range of 50–60 seconds was initiated. After removal of the thoracic 
epidural catheter high dose of low-molecular-weight heparin (8000 IU of Mono Embolex®, 
Novartis Pharma GmbH, Nürnberg, Germany) was applicated. To improve patient saftey and 
to reduce the risk of haematoma, we strictly observed the guidelines of the European Society 
of Anaesthesiology for regional anaesthesia and antithrombotic agents, especially the 
recommended time intervals between the administration of anticoagulants/platelet 
aggregation inhibitors, the thoracic epidural blackade and the removal of catheters [12]. 
During and after HITHOC treatment the safety of the medical staff including the 
anaesthesiologist is very important. Routes of exposure to the cytotoxic agents include 
inhalation, ingestion, injection, and skin contact. It is necessary to reduce risks associated 
with exposure through the proper use of certain specialized medical supplies and equipment. 
Some essentials contain imperious sterile gowns, unpowdered latex gloves, a respirator mask, 
a spill kit, protective eyewear, an impenetrable hazardous waste container, appropriate 
cytotoxic agent labels, and specially marked linen bags. Body fluids and blood from patients 
undergoing chemotherapy treatment are said to be contaminated for up to 48 hours, starting 
from the time of administering the dosage. Institutions in which cytotoxic agents are 
administered should use guidelines to develop policies, procedures, and educational programs 
to protect medical staff [13]. 
The present data were collected retrospectively from the patient’s notes, the anaesthesia 
protocols (Medlinq-Anästhesie®, Medlinq, Hamburg, Germany), digitally acquired ICU files 
(MetaVision®, Essen-Kettwig, Germany), and the electronic medical records of the acute 
pain service (Medlinq-Schmerzvisite®, Medlinq, Hamburg, Germany). Statistical analysis 
was performed by independent-samples t-test (SPSS version 18, Dynelytics AG, Zürich, 
Switzerland). A p value less than 0.05 was considered statistically significant. 
Results 
Between September 2008 and April 2013, a total of 20 patients with pleural malignancies 
were retrospectively enrolled in this study. Patient characteristics are summarized in Table 1. 
There were 13 male (65%) and 7 female (35%) patients with a mean age of 55 ± 13,6 years . 
Ten patients (50%) had histologically confirmed malignant pleural mesothelioma. Ten 
patients (50%) with pleural manifestation of thymoma (Masaoka stage IVa) were included in 
this trial as well. 
  
Table 1 Demographic characteristics of the 20 patients 
Parameters N or mean ± standard deviation (range) 
Age (years) 55 ± 13,6 (25–72) 
Sex (male,female) 13 vs. 7 
Weight (kg) 76 ± 8,2 (68–93) 
Height (cm) 172 ± 13,3 (160–185) 
BMI (kg.m−2) 26.4 ± 3,1 (20–31) 
ASA Grade - 
II 6 
III 13 
IV 1 
(BMI: Body-Mass-Index, ASA: American Society of Anaesthesiologists). 
13 of 20 patients (65%) received an epidural catheter before induction of general anaesthesia, 
four patients refused, two placements were unsuccessful. One epidural catheter was 
uneventfully removed after a positive blood aspiration. Patients with TEA experienced 
clinically measurable lower pain intensity in the first 5 days after surgery. Statistically 
significant lower NRS values were found in the first 60 h after the operation. Mean duration 
of epidural catheter was 5,2 ± 2 days . Postoperative pain intensity in the two groups is shown 
in Table 2 and Figure 1. 
Table 2 Comparison of pain intensity between the two groups (mean ± standard 
deviation) on the first 5 days after surgery at 8 am and 6 pm 
Day after surgery Time of the day NRS (mean ± SD) TEA NRS (mean ± SD) no TEA p-value 
0 6 pm 0.80 ± 1.47 5.17 ± 1.47 .00* 
1 8 am 1.50 ± 1.90 4.67 ± 2.80 .017* 
1 6 pm 1.40 ± 1.34 4.50 ± 1.97 .002* 
2 8 am 1.67 ± 1.65 4.17 ± 1.32 .009* 
2 6 pm 1.80 ± 1.39 3.17 ± 0.75 .046* 
3 8 am 1.38 ± 1.18 3.50 ± 0.83 .003* 
3 6 pm 1.00 ± 1.22 2.00 ± 1.54 .186 
4 8 am 0.88 ± 1.12 1.83 ± 1.60 .212 
4 6 pm 1.25 ± 1.48 1.50 ± 1.22 .744 
5 8 am 1.29 ± 1.38 1.83 ± 0.98 .435 
5 6 pm 0.86 ± 0.89 1.67 ± 0.51 .78 
(*p < 0,05 vs. NRS no TEA, NRS: Nummeric Rating Scale, TEA: Thoracic Epidural Analgesia. 
Figure 1 Comparison of pain intensity between the two groups (TEA vs. No TEA) on the 
first 5 days after surgery at 8 am and 6 pm. 
During OLV no respiratory complications occurred in any patient. The oxygen saturation and 
the arterial blood gas measurements did not show any signs of hypoxemia or acidosis induced 
by hypercapnia. 
After application of the priming volume at the beginning of HITHOC ten patients (50%) had 
a considerable decrease in blood pressure, three patients (15%) additionally developed 
tachycardia over 100 beats per minute. Simultaneously the mean central venous pressure 
ranged from 14 to 18 and the peak airway pressure from 26 to 31 mmHg. Meanwhile the 
mean amount of noradrenaline being infused had to be increased from 0.21 to 0.54 mg•h−1. 
Five patients (25%) additionally received dobutamine at a dose of 10–20 mg•h−1, one patient 
(5%) adrenaline at a dose of 0,2 mg•h−1. After strong increase in central venous pressure at 
the beginning of the intrathoracic perfusion, one patient showed a short episode of asystole 
(~60 sec.). It was treated successfully by cardiopulmonary resuscitation, application of 
adrenalin, and reduction of the intrathoracic ringer’s lactate by the perfusion system. There 
was no evidence of fluid absorption from the pleural space. Extubation was performed 8 
hours after surgery without any neurological deficit. 
During surgical cytoreduction the average body temperature decreased from 36.6 to 36.3 ± 
0,6°C and increased during the HITHOC to 38.4 ± 0,6°C . All patients were passively (with 
three patients actively) cooled at the beginning of the HITHOC (Bair Hugger®, Arizant 
Medical, Inc., Eden Prairie, MN, USA). 
Severe postoperative complications requiring surgical correction occurred in three patients 
(15%). Two mesothelioma patients underwent timely reoperation due to a rupture of the 
diaphragm, one thymoma patient due to a chylothorax. The thymoma patient was readmitted 
postoperatively to the ICU for 12 days because of respiratory insufficiency and fulminant 
sepsis. In addition conservative treatment was successful in one patient who experienced 
subclavian and axillary thrombosis on the ipsilateral side of surgery. 
The median duration of the entire surgery including anaesthetisation, intervention and 
HITHOC was 275 ± 83 minutes . Timely extubation directly after surgery was performed in 
15 patients (75%), whereas five patients required mechanical ventilation on ICU - three 
patients with TEA (23%) and two patients without (28,5%) (p = 0,625). No significant 
difference resulted in length of postoperative mechanical ventilation between the two groups 
(406 ± 245 versus 272 ± 60 minutes) (p = 0,144) . The average length of stay on the ICU was 
1 ± 0,6 days and the overall median hospital stay was 15 ± 9 days in patients with TEA and 
16 ± 10 days in patients without (p = 0,698). One patient died due to a rupture of the 
diaphragm patch causing pericardial tamponade followed by severe cerebral hypoxia on the 
second postoperative day after EPP. No further pulmonary complications were observed. 
There was no other in-hospital mortality or death within 30 days after operation among the 
other 19 patients in this study. 
While in surgery, all patients received a mean volume of 2531 ml crystalloid and 719 ml 
colloid solutions. Seven patients (35%) with either a hemoglobin concentration below 8 g/dl 
or clinical transfusion triggers required PRBC. No transfusion of fresh frozen plasma (FFP) 
or other clotting factors were necessary in any patient. Urine output per kg of body weight 
was about 2.5 ml/h (Table 3). 
Table 3 Intraoperative fluid management 
Fluids n (patients) Mean ± standard deviation (range) in ml 
Crystalloids 20 2531 ± 734 (1500–3500) 
Colloids 20 719 ± 466 (0–1500) 
FFP 0 0 
PRBC 7 392 ± 196 (0–750) 
Urine 20 877 ± 523 (250–3000) 
(FFP: Fresh Frozen Plasma, PRBC: Packed Red Blood Cells). 
Postoperative blood results on ICU (Table 4) suggested that there were only two patients 
(10%) with the presence of abnormal blood clotting. The mean hemoglobin values were over 
8 g/dl in all 20 patients. One patient developed an acute renal insufficiency with a creatinine 
concentration of 2.7 mg/dl three days after surgery. Dialysis was not necessary in this case. 
All other patients did not show any significant alterations compared to control levels. 
Table 4 Pre- and postoperative laboratory parameters: mean ± standard deviation, 
(range) 
Variables Preoperative Parameters Postoperative 
Parameters (Day 0) 
Postoperative 
Parameters (Day 3) 
Hemoglobin (g/dl) 12.4 ± 1.93, (8.4 – 15.3) 9.92 ± 1.16, (8.6 – 11.9)  
Hematocrit (%) 36.4 ± 5.56, (22.5 – 43.7) 28.9 ± 3.36, (24.6 – 33.6)  
Creatinine (mg/dl) 0.85 ± 0.18, (0.66 – 1.20) 0.84 ± 0.17, (0.45 – 1.25) 0.97 ± 0.49, (0.44 - 2.7) 
Prolonged time (%) 105 ± 8.57, (92 – 127) 80.8 ± 11.12, (46–92)  
PTT (sec) 30.7 ± 3.53, (25.8 – 38) 32.7 ± 6.94, (24.1 – 52.0)  
Thrombocytes (/nl) 347 ± 135.5, (178 – 699) 274 ± 97.5, (149–511)  
Discussion 
The indication for cytoreductive surgery in combination with HITHOC was restricted for the 
treatment of malignant pleural mesothelioma and advanced thymoma with pleural spread for 
a long time. During the last years a few authors showed that this multimodal approach could 
be a feasible treatment option for patients with pleural dissemination of pseudomyxoma 
peritonei, peritoneal mesothelioma or epithelian ovarian cancer, as well [9,14,15]. Hence the 
indications for this treatment are probably growing, and not only at specialized medical 
centers [16]. Due to the complex pathophysiological changes accompanying P/D or EPP and 
HITHOC, careful scheduling and implementation of the anaesthesia is of utmost importance 
for patient safety. 
At the beginning of chemotherapy perfusion, thoracic filling with hyperthermic ringer’s 
lactate causes an increase in intrathoracic pressure. Depending on the volume of solution, a 
mediastinal shift to the ventilated lung resulting in an increase in airway pressure and a 
reduction of the functional residual capacity can be observed [17-19]. Therefore obstruction 
of the inferior and superior vena cava decreasing venous return to the heart, and direct cardiac 
compression can lead to a fall in cardiac output. In our understanding these 
pathophysiological alterations resulted in a reduction of the arterial blood pressure and the 
tissue perfusion, followed by a considerable rise of catecholamine levels in this trial. In 
addition, compression-induced increase of the myocardial wall tension and the heart rate can 
also cause an acute rise of the oxygen demand, and in combination with reduced coronary 
perfusion pressure exacerbate existing cardiac disease in patients with coronary artery 
disease. 
Perioperative fluid management is an important cornerstone of hemodynamic stability in 
patients undergoing cytoreductive surgery followed by HITHOC and a challenge for each 
anaesthesiologist. Recent studies and reviews have repeatedly demonstrated a strong 
correlation between liberal fluid administration and the incidence of postoperative lung 
edema or ALI. Especially in patients undergoing lung surgery, excessive volume infusion can 
contribute to respiratory failure with increased postoperative mortality [20-22]. On the other 
hand, an adequate perioperative fluid therapy is important to reduce the risk of 
chemotherapy-related postoperative renal insufficiency. Therefore we recommend a 
perioperative forced diuresis (>100 ml/h), which will be continued for 3 days after surgery. 
Furthermore the aim of perioperative fluid therapy also is to replace fluid losses, to maintain 
adequate intravascular volume in the cytoreductive phase, and to ensure a sufficient preload 
before starting the chemotherapy perfusion, with the above-mentioned pathophysiological 
changes. For this the implementation of hemodynamic monitoring (pulmonary artery 
catheter, pulse contour cardiac output) could be an adjuvant tool. In addition the application 
of the priming volume must be started under accurate control of hemodynamic and 
ventilatory parameters, and from close consultation with the surgeons. For compensation of 
hemodynamic disorders, vasopressor and inotropic drugs have to be prepared before starting 
surgery. Three principles could help to prevent complication seen in our patients: an adequate 
fluid therapy, a careful filling of the thoracic side, and an early use of catecholamines. 
Maintaining patient normothermia during the whole procedure should be another goal of 
anaesthetic management. Therefore the patient’s body temperature was continuously 
evaluated buccally and esophageally. During the first phase of anaesthesia (induction, 
cytoreductive surgery) patients have to be protected from loss of body heat. By using 
warming blankets and heated fluid infusions, excessive hypothermia could be prevented in 
our patients. In only one case a temperature was measured under 35.5°C. Recent studies 
showed that perioperative hypothermia occurs in more than 70% of patients in the 
perioperative phase and can lead to several complications: increase in blood loss during 
surgery by impairing platelet function and clotting factor enzyme function, increase in the 
incidence of surgical wound infection induced by peripheral vasoconstriction with a 
significant reduction of subcutaneous oxygen tension and an impairment in immune function, 
increase in heart rate and oxygen demand in the presence of shivering [23-25]. Additionally 
Frank et al. reported a higher prevalence of myocardial ischemia and ventricular tachycardia 
in patients with perioperative hypothermia [26]. Otherwise during HITHOC temperature in 
the pleural space rises up to about 42°C with the risk of systemic hyperthermia. As we know 
from patients undergoing cytoreductive surgery and HIPEC, elevated body temperatures can 
increase metabolic rates and oxygen demand followed by tachycardia, higher end-tidal CO2 
concentration and a metabolic acidosis [27,28,17,18]. The development of myocardial 
ischemia is a possible complication especially for patients with existing coronary artery 
disease. Hyperthermia can also lead to pulmonary edema and ventilator-induced acute lung 
injury [29,30]. In addition it may contribute to development of neurocognitive dysfunction, 
which is often described during the rewarming process after cardiopulmonary bypass for 
cardiac surgery [31]. Animal experiments showed that hyperthermia with temperatures over 
43°C can lead to neurological and electrophysiological alterations in peripheral nerves like 
such as phrenic, vagus and recurrent laryngeal nerves [9,32]. Thereby hyperthermia can 
possibly contribute to a modified apperception of pain. To avoid systemic hyperthermia in 
this phase, we used cooled infusions and cooling blankets. In spite of extensive cooling nine 
of our patients developed core body temperatures above 38.0°C, three patients even above 
38.5°C. There were no hyperthermia-induced complications in the current cohort of patients. 
Regional intracavitary chemotherapiy perfusion has the advantage of an improved 
distribution of the drug in the pleural space and a higher local concentration of the 
chemotherapeutic agent in contrast to systemic chemotherapy. Additionally, HITHOC is 
known to enhance the cytotoxicity of some chemotherapeutics, to increase the penetration 
depth, and to produce synergistic antineoplastic effects. Although the systemic toxicity could 
be reduced, significant blood concentrations of the cytostatic agents were measured [33-35]. 
While toxicities of cisplatin include ototoxicity, gastrotoxicity, myelosuppression and allergic 
reactions, the main dose-limiting side effect is nephrotoxicity. To prevent this cytostatica-
induced tubular nephrotoxicity, the aim of the anaesthetist should be a forced perioperative 
hydration and diuresis. Therefore a urine flow greater than 0.5 ml kg−1 h−1 should be 
achieved, although no randomized studies can acknowledge this approach [36]. 
The retrospective analysis of our data shows that about one third of the patients (35%) 
received a PRBC transfusion or cell saver blood with subsequent irradiation (50 Gy). 
Comparable transfusion rates (34.6%) were reported for patients undergoing cytoreductive 
surgery and HIPEC [18]. Furthermore, due to an impairment of coagulation, about 45% of 
HIPEC patients received a transfusion of fresh frozen plasma as well. Otherwise laboratory 
analysis of our patients demonstrated no such disturbance of coagulation and so the 
transfusion of fresh frozen plasma or thrombocytes was not necessary. The reason for 
coagulopathy may be a large volume shift and a significant protein loss depending on the 
degree of decortication and the volume of fluid resuscitation. In our collective we also could 
not find any direct effect of the HITHOC itself [18,37]. Due to a large raw peritoneal surface 
area, impairment of coagulation is more often associated with cytoreductive surgery of the 
abdominal than of the thoracic cavity. 
Thoracotomy induces severe postoperative pain and impairment of pulmonary function. 
Therefore the TEA is commonly considered the “gold standard” [38]. In our trial, TEA was 
superior to peroral opioid and non-opioid analgesics. Significantly lower values of NRS at 
rest were found in the first 60 h after surgery in the epidural group. No significant difference 
resulted in duration of postoperative mechanical ventilation, incidence of postoperative 
pulmonary complications or median length of hospital stay between the two groups. 
Postoperative lung function testing, which would probably show differences between the two 
groups were, not part of standard postoperative management. However, multiple former 
studies have also demonstrated a superior functional residual capacity, vital capacity and 
forced exspiratory volume after the administration of epidural analgesia, and in addition, an 
improvement of the bowel motility and function, the postoperative vigilance and the balance 
of myocardial oxygen supply and demand [39-41]. 
Conclusion 
Thoracic cytoreductive surgery and intraoperative HITHOC is an innovative, multimodal 
approach with a potentially curative intention for patients with primary and secondary 
malignant pleural tumors. In this article we reviewed the pathophysio-logical alterations and 
emphasized anaesthetic management strategies to avoid or minimize complications and to 
improve peri- and postoperative care of patients. 
Consent statement 
Written informed consent was obtained from the patients for publication of this case report 
and any accompanying images. A copy of the written consent is available for review by the 
Editor-in-Chief of this journal. 
Abbreviations 
ALI, Acute lung injury; CPAP, Continuous positive airway pressure; EPP, Extrapleural 
pneumonectomy; FFP, Fresh frozen plasma; Fr, French; Gy, Gray; HITHOC, Hyperthermic 
intrathoracic chemotherapy perfusion; HIPEC, Intraperitoneal hyperthermic perfusion 
chemotherapy; ICU, Intensive care unit; NRS, Numerical rating scale; OLV, One lung 
ventilatíon; PCEA, Patient-controlled epidural analgesia; Peep, Positive end-exspiratory 
pressure; PLV, Protective lunge ventilation; P/D, Pleurectomy/Decortication; PRBC, Packed 
red blood cells; TEA, Thoracic epidural analgesia 
Competing interest 
The authors declare that they have no competing interests. 
Authors’ contributions 
CK and YZ conceived of the study, CK collected the present data, performed the statistical 
analysis and drafted the manuscript, MR, HSH and BG participated in its design and 
coordination and helped to draft the manuscript. All authors read and approved the final 
manuscript. 
References 
1. Yellin A, Simansky DA, Paley M, Refaely Y: Hyperthermic pleural perfusion with 
cisplatin: early clinical experience. Cancer 2001, 92:2197–2203. 
2. De Bree E, van Ruth S, Baas P, Rutgers EJ, van Zandwijk N, Witkamp AJ, Zoetmulder 
FA: Cytoreductive surgery and intraoperative hyperthermic intrathoracic 
chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of 
thymoma. Chest 2002, 121:480–487. 
3. Van Ruth S, Baas P, Haas R, Rutgers E, Verwaal V, Zoetmulder FA: Cytoredictive 
surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for 
stage I malignant pleural mesothelioma. Ann Surg Oncol 2003, 10:176–182. 
4. Piso P, Dahlke MH, Ghali N, Iesalnieks I, Loss M, Popp F, von Breitenbuch P, Agha A, 
Lang SA, Kullmann F, Schlitt HJ: Multimodality treatment of peritoneal carcinomatosis 
from colorectal cancer: first results of a new German centre for peritoneal surface 
malignancies. Int J Colorectal Dis 2007, 22(11):1295–1300. 
5. Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A: Resection and perfusion 
thermochemotherapy: a new approach for the treatment of thymic malignancies with 
pleural spread. Ann Thorac Surg 2001, 72:366–370. 
6. Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B, Diez C, Hofmann H-S: 
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for 
malignant pleural tumors: perioperative management and clinical experience. Eur J 
Cardiothorac Surg 2013, 43(4):801–807. 
7. Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, 
Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ: Phase I to II study of 
pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin 
lavage for mesothelioma. J Clin Oncol 2006, 24(10):1561–1567. 
8. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch 
VW: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical 
management of malignant pleural mesothelioma: results in 663 patients. J Thorac 
Cardiovasc Surg 2008, 135(3):620–626. 
9. Dang A, Mansfield P, Ilsin B, Hightower C, Aravindan N, Rice D, Riedel B: 
Intraoperative hyperthermic intrathoracic chemotherapy for pleural extension of 
pseudomyxoma peritonei. J Cardiothorac Vasc Anesth 2007, 21:265–268. 
10. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaihof E, Fleischmann KE, Freeman 
WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF: ACC/AHA 2007 Guidelines 
on perioperative cardiovascular evaluation and care for noncardiac surgery: executive 
summary. Circulation 2007, 116(17):1971–1996. 
11. Geldner G, Kelm M, Leschke M, Mertens E, Meyer C, Mössner J, Obertacke U, Schwenk 
W, Wappner F, Zwissler B: Präoperative Evaluation erwachsener Patienten vor 
elektiven, nicht, kardiochirurgischen Eingriffen. Gemeinsame Empfehlung der DGAI, 
DGI, DGCH. Anästh Intensivmed 2010, 11:S788–S796. 
12. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM: Regional 
anaesthesia and antithrombotic agents: recommendations of the European Society of 
Anaesthesiology. Eur J Anaesthesiol 2010, 27:999–1015. 
13. González-Bayón L, González-Moreno S, Ortega-Pérez G: Safety considerations for 
operating room personnel during hyperthermic intraoperative intraperitoneal 
chemotherapy perfusion. Eur J Surg Oncol 2006, 32(6):619–624. 
14. Farivar AS, Louie BE, Aye RW, Horton MP, Vallières E: Extrapleural 
pneumonectomy for primary pleural mullerian tumor in a young woman. Ann Thorac 
Surg 2012, 93(1):e1–e2. 
15. Sugarbaker PH, Chang D, Stuart OA: Hyperthermic intraoperative thoracoabdominal 
chemotherapy. Gastroenterol Res Pract 2012, 2012:623417. 
16. Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH: Hemodynamic and 
cardiac function parameters during heated intraoperative intraperitoneal 
chemotherapy using the open “coliseum technique”. Ann Surg Oncol 2000, 7(4):296–300. 
17. Kanakoudis F, Petrou A, Michaloudis D, Chortaria G, Konstantinidou A: Anaesthesia 
for intra-peritoneal perfusion of hyperthermic chemotherapy. Haemodynamic changes, 
oxygen consumption and delivery. Anaesthesia 1996, 51:1033–1036. 
18. Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M: Peri-operative anaesthetic 
management of cytoreductive surgery with hyperthermic intraperitoneal 
chemotherapy. Anaesthesia 2008, 63(4):389–395. 
19. Raspe C, Piso P, Wiesenack C, Bucher M: Anesthetic management in patients 
undergoing hyperthermic chemotherapy. Curr Opin Anaesthesiol 2012, 25:348–355. 
20. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Londorff-Larsen K, 
Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, 
Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, 
Graungaard B, Pott F, Danish Study Group on Perioperative Fluid Therapy: Effects of 
intravenous fluid restriction on postoperative complications: comparison of two 
perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 
2003, 238:641–648. 
21. Zausig Y, Weigand M, Graf BM: Perioperatives Flüssigkeitsmanagement. Anaesthesist 
2006, 53:371–390. 
22. Licker M, de Perrot M, Spiliopoulos A, Robert J, Diaper J, Chevalley C, Tschopp J-M: 
Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesth Analg 
2003, 97:1558–1565. 
23. Bräuer A, Perl T, Quintel M: Perioperative thermal management. Anaesthesist 2006, 
55(12):1321–1339. 
24. Putzu M, Casati A, Berti M, Pagliarini G, Fanelli G: Clinical complications, monitoring 
and management of perioperative mild hypothermia: anesthesiological features. Acta 
Biomed 2007, 78(3):163–169. 
25. Scott EM, Buckland R: A systematic review of intraoperative warming to prevent 
postoperative complications. AORN J 2006, 83(5):1104. 1107–13. 
26. Frank SM, Fleisher LA, Breslow MJ, Higgins MS, Olson KF, Kelly S, Beattie C: 
Perioperative maintenance of normothermia reduces the incidence of morbid cardiac 
events: A randomized clinical trial. JAMA 1997, 277:1127–1134. 
27. Cafiero T, Di Iorio C, Di Minno RM, Sivolella G, Confuorto G: Noninvasive cardiac 
monitoring by aortic blood flow determination in patients undergoing hyperthermic 
intraperitoneal intraoperative chemotherapy. Minerva Anestesiol 2006, 72:207–215. 
28. Schmidt C, Moritz S, Rath S, Grossmann E, Wiesenack C, Piso P, Graf BM, Bucher M: 
Perioperative management of patients with cytoreductive surgery for peritoneal 
carcinomatosis. J Clin Oncol 2009, 100:297–301. 
29. Mustafa KY, Selig WM, Burhop KE, Minnear FL, Malik AB: Hyperthermia-induced 
pulmonary edema. J Appl Physiol 1986, 60(6):1980–1985. 
30. Suzuki S, Hotchkiss JR, Takahashi T, Olson D, Adams AB, Marini JJ: Effect of core 
body temperature on ventilator-induced lung injury. Crit Care Med 2004, 32(1):144–149. 
31. Ginsberg MD, Busto R: Combating hyperthermia in acute stroke: a significant 
clinical concern. Stroke 1998, 29(2):529–534. 
32. Vujaskovic Z, Gillette SM, Powers BE, LaRue SM, Gillette EL, Borak TB, Scott RJ, 
Ryan TP, Colacchio TA: Effects of intraoperative hyperthermia on peripheral nerves: 
neurological and electrophysiological studies. Int J Hyperthermia 1994, 10(1):41–49. 
33. Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, 
Markman M: Intrapleural cisplatin and mitomycin for malignant mesothelioma 
following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992, 10(6):1001–1006. 
34. Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO: 
Pleural space perfusion with cisplatin in the multimodality treatment of malignant 
mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999, 
117(4):759–765. 
35. Ried M, Diez C, Neu R, Hofmann H-S: Kombinierte Technik der chirurgischen 
Zytoreduktion und hyperthermen intrathorakalen Chemotherapieperfusion. Z Herz-
Thorax-Gefäßchir 2010, 24(5):277–284. 
36. Sear JW: Kidney dysfunction in the postoperative period. Br J Anaesth , 95(1):20–
32. Epub 2004 Nov 5. 
37. Cooksley TJ, Haji-Michael P: Post-operative critical care management of patients 
undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). 
World J Surg Oncol 2011, 9:169. 
38. Joshi GP, Bonnet F, Shah R, Wilkinson RC, Camu F, Fischer B, Neugebauer EA, Rawal 
N, Schug SA, Simanski C, Kehlet H: A systematic review of randomized trials evaluating 
regional techniques for postthoracotomy analgesia. Anesth Analg 2008, 107(3):1026–
1040. Review. 
39. Litz RJ, Bleyl JU, Frank M, Albrecht DM: Combined anesthesia procedures. 
Anaesthesist 1999, 48(6):359–372. 
40. Handley GH, Silbert BS, Mooney PH, Schweitzer SA, Allen NB: Combined general 
and epidural anesthesia versus general anesthesia for major abdominal surgery: 
postanesthesia recovery characteristics. Reg Anesth 1997, 22(5):435–441. 
41. Brodner G, Meissner A, Rolf N, Van Aken H: Thoracic epidural anesthesia–more than 
an anesthesia technique. Anaesthesist 1997, 46(9):751–762. 
Figure 1
